<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2025"
  xmlns:ffd="http://xbrl.sec.gov/ffd/2025"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef
      xlink:href="https://xbrl.sec.gov/ffd/2025/ffd-2025.xsd"
      xlink:type="simple"/>
    <context id="C_b67b64d4-632e-4174-b75e-0818148a4680">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001817241</identifier>
        </entity>
        <period>
            <startDate>2026-03-10</startDate>
            <endDate>2026-03-10</endDate>
        </period>
    </context>
    <context id="C_1f6ba287-de75-4191-aff3-3d93b1ebd441">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001817241</identifier>
            <segment>
                <xbrldi:typedMember dimension="ffd:OfferingAxis">
                    <dei:lineNo>2</dei:lineNo>
                </xbrldi:typedMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-03-10</startDate>
            <endDate>2026-03-10</endDate>
        </period>
    </context>
    <context id="C_5b562405-3aa3-436a-aaf1-13bdf1f0b88b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001817241</identifier>
            <segment>
                <xbrldi:typedMember dimension="ffd:OfferingAxis">
                    <dei:lineNo>1</dei:lineNo>
                </xbrldi:typedMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-03-10</startDate>
            <endDate>2026-03-10</endDate>
        </period>
    </context>
    <context id="C_661ecd0f-8d3e-4507-b11b-166454042432">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001817241</identifier>
            <segment>
                <xbrldi:typedMember dimension="ffd:OfferingAxis">
                    <dei:lineNo>3</dei:lineNo>
                </xbrldi:typedMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-03-10</startDate>
            <endDate>2026-03-10</endDate>
        </period>
    </context>
    <unit id="U_pure">
        <measure>pure</measure>
    </unit>
    <unit id="U_shares">
        <measure>shares</measure>
    </unit>
    <unit id="U_USD">
        <measure>iso4217:USD</measure>
    </unit>
    <ffd:PrevslyPdFlg
      contextRef="C_1f6ba287-de75-4191-aff3-3d93b1ebd441"
      id="F_5cd5cdd6-a5ea-4e7f-910a-85312f884afd">false</ffd:PrevslyPdFlg>
    <ffd:PrevslyPdFlg
      contextRef="C_661ecd0f-8d3e-4507-b11b-166454042432"
      id="F_24ae2f6f-0223-446d-8755-80c4b79daba7">false</ffd:PrevslyPdFlg>
    <dei:EntityCentralIndexKey
      contextRef="C_b67b64d4-632e-4174-b75e-0818148a4680"
      id="F_daeefe27-1f74-40c7-98ab-e11d1b996991">0001817241</dei:EntityCentralIndexKey>
    <ffd:PrevslyPdFlg
      contextRef="C_5b562405-3aa3-436a-aaf1-13bdf1f0b88b"
      id="F_165ccc93-2a4b-4d80-9068-8af5bfa3bfc2">false</ffd:PrevslyPdFlg>
    <ffd:OffsetTableNa
      contextRef="C_b67b64d4-632e-4174-b75e-0818148a4680"
      id="F_27fd91ec-e77d-4eb7-aeb3-5bc2c0be73f9">N/A</ffd:OffsetTableNa>
    <ffd:FeeExhibitTp
      contextRef="C_b67b64d4-632e-4174-b75e-0818148a4680"
      id="F_b1718021-849d-4235-9fd7-30e0f625110e">EX-FILING FEES</ffd:FeeExhibitTp>
    <ffd:FormTp
      contextRef="C_b67b64d4-632e-4174-b75e-0818148a4680"
      id="F_45eb15bf-f9b5-4c9d-a5ad-127ae03d66d4">S-8</ffd:FormTp>
    <ffd:SubmissnTp
      contextRef="C_b67b64d4-632e-4174-b75e-0818148a4680"
      id="F_3d175505-6736-4bf3-9883-805136f34ba9">S-8</ffd:SubmissnTp>
    <dei:EntityRegistrantName
      contextRef="C_b67b64d4-632e-4174-b75e-0818148a4680"
      id="F_db17813b-6b9f-41d6-a654-2d272be16891">Artiva Biotherapeutics, Inc.</dei:EntityRegistrantName>
    <ffd:OfferingSctyTp
      contextRef="C_5b562405-3aa3-436a-aaf1-13bdf1f0b88b"
      id="F_67000107-d360-4ce6-913d-38b3f525733e">Equity</ffd:OfferingSctyTp>
    <ffd:OfferingSctyTitl
      contextRef="C_5b562405-3aa3-436a-aaf1-13bdf1f0b88b"
      id="F_dd050352-b842-4346-a722-367c2fd6da3b">Common Stock, $0.0001 par value per share, reserved for issuance pursuant to the 2024 Equity Incentive Plan</ffd:OfferingSctyTitl>
    <ffd:FeesOthrRuleFlg
      contextRef="C_5b562405-3aa3-436a-aaf1-13bdf1f0b88b"
      id="F_f31aec3f-7670-4327-96ba-d74c1771bd27">true</ffd:FeesOthrRuleFlg>
    <ffd:AmtSctiesRegd
      contextRef="C_5b562405-3aa3-436a-aaf1-13bdf1f0b88b"
      decimals="0"
      id="F_fd54167a-312b-456b-9be8-74e835ae487d"
      unitRef="U_shares">1229777</ffd:AmtSctiesRegd>
    <ffd:MaxOfferingPricPerScty
      contextRef="C_5b562405-3aa3-436a-aaf1-13bdf1f0b88b"
      decimals="2"
      id="F_7abba464-86f0-48f4-a58c-b085f78c754c"
      unitRef="U_USD">5.43</ffd:MaxOfferingPricPerScty>
    <ffd:MaxAggtOfferingPric
      contextRef="C_5b562405-3aa3-436a-aaf1-13bdf1f0b88b"
      decimals="2"
      id="F_d388a04a-22bd-401c-affb-0188046a6521"
      unitRef="U_USD">6677689.11</ffd:MaxAggtOfferingPric>
    <ffd:FeeRate
      contextRef="C_5b562405-3aa3-436a-aaf1-13bdf1f0b88b"
      decimals="8"
      id="F_e9c8c7d3-69a9-4993-9c01-7417974c9b5b"
      unitRef="U_pure">0.0001381</ffd:FeeRate>
    <ffd:FeeAmt
      contextRef="C_5b562405-3aa3-436a-aaf1-13bdf1f0b88b"
      decimals="2"
      id="F_b49e0b91-af99-4fe0-8909-016f3ddefcc7"
      unitRef="U_USD">922.19</ffd:FeeAmt>
    <ffd:OfferingSctyTp
      contextRef="C_1f6ba287-de75-4191-aff3-3d93b1ebd441"
      id="F_b66776c6-d7b7-40ea-8690-738b4244ea1f">Equity</ffd:OfferingSctyTp>
    <ffd:OfferingSctyTitl
      contextRef="C_1f6ba287-de75-4191-aff3-3d93b1ebd441"
      id="F_63c243fc-8312-4be5-8935-a8bbf80648d4">Common Stock, $0.0001 par value per share, reserved for issuance pursuant to the 2024 Employee Stock Purchase Plan</ffd:OfferingSctyTitl>
    <ffd:FeesOthrRuleFlg
      contextRef="C_1f6ba287-de75-4191-aff3-3d93b1ebd441"
      id="F_f1252e3e-c6ac-4861-8958-8416464170ee">true</ffd:FeesOthrRuleFlg>
    <ffd:AmtSctiesRegd
      contextRef="C_1f6ba287-de75-4191-aff3-3d93b1ebd441"
      decimals="0"
      id="F_9744374c-af7c-4084-9e27-4edcd45e8548"
      unitRef="U_shares">245955</ffd:AmtSctiesRegd>
    <ffd:MaxOfferingPricPerScty
      contextRef="C_1f6ba287-de75-4191-aff3-3d93b1ebd441"
      decimals="2"
      id="F_32d4ddba-7507-483e-b604-f29ffb11815c"
      unitRef="U_USD">4.62</ffd:MaxOfferingPricPerScty>
    <ffd:MaxAggtOfferingPric
      contextRef="C_1f6ba287-de75-4191-aff3-3d93b1ebd441"
      decimals="2"
      id="F_dca948f2-3c8a-4a30-a4b1-758686595d13"
      unitRef="U_USD">1136312.1</ffd:MaxAggtOfferingPric>
    <ffd:FeeRate
      contextRef="C_1f6ba287-de75-4191-aff3-3d93b1ebd441"
      decimals="8"
      id="F_1a689417-2bc2-430f-80a2-67b8b26b416b"
      unitRef="U_pure">0.0001381</ffd:FeeRate>
    <ffd:FeeAmt
      contextRef="C_1f6ba287-de75-4191-aff3-3d93b1ebd441"
      decimals="2"
      id="F_8d2aa382-c82e-45af-aa4f-235422e4a2af"
      unitRef="U_USD">156.93</ffd:FeeAmt>
    <ffd:OfferingSctyTp
      contextRef="C_661ecd0f-8d3e-4507-b11b-166454042432"
      id="F_6b3221f2-8508-4419-84ca-8322f6a6e2bf">Equity</ffd:OfferingSctyTp>
    <ffd:OfferingSctyTitl
      contextRef="C_661ecd0f-8d3e-4507-b11b-166454042432"
      id="F_3603d033-a044-4de3-aac3-0ed0431f37e3">Common Stock, $0.0001 par value per share, reserved for issuance pursuant to the 2025 Inducement Plan</ffd:OfferingSctyTitl>
    <ffd:FeesOthrRuleFlg
      contextRef="C_661ecd0f-8d3e-4507-b11b-166454042432"
      id="F_78b6a7bc-b306-4a3c-9ec4-1e42584120fe">true</ffd:FeesOthrRuleFlg>
    <ffd:AmtSctiesRegd
      contextRef="C_661ecd0f-8d3e-4507-b11b-166454042432"
      decimals="0"
      id="F_e23898bd-6795-4dc2-97b8-2b1b2e24d1d9"
      unitRef="U_shares">600000</ffd:AmtSctiesRegd>
    <ffd:MaxOfferingPricPerScty
      contextRef="C_661ecd0f-8d3e-4507-b11b-166454042432"
      decimals="2"
      id="F_81fd0a9d-9fd1-41ff-b8d7-8c6eb7b8e8b7"
      unitRef="U_USD">5.43</ffd:MaxOfferingPricPerScty>
    <ffd:MaxAggtOfferingPric
      contextRef="C_661ecd0f-8d3e-4507-b11b-166454042432"
      decimals="2"
      id="F_0e7937d6-a35e-4eff-b097-34435a6d172a"
      unitRef="U_USD">3258000</ffd:MaxAggtOfferingPric>
    <ffd:FeeRate
      contextRef="C_661ecd0f-8d3e-4507-b11b-166454042432"
      decimals="8"
      id="F_48e30506-3de7-4281-893b-9becbe796807"
      unitRef="U_pure">0.0001381</ffd:FeeRate>
    <ffd:FeeAmt
      contextRef="C_661ecd0f-8d3e-4507-b11b-166454042432"
      decimals="2"
      id="F_833114a5-011f-4434-b2d8-96902af8bcd5"
      unitRef="U_USD">449.93</ffd:FeeAmt>
    <ffd:TtlOfferingAmt
      contextRef="C_b67b64d4-632e-4174-b75e-0818148a4680"
      decimals="2"
      id="F_d9dbef7c-af9d-44f0-92b2-297b1ab0ed80"
      unitRef="U_USD">11072001.21</ffd:TtlOfferingAmt>
    <ffd:TtlFeeAmt
      contextRef="C_b67b64d4-632e-4174-b75e-0818148a4680"
      decimals="2"
      id="F_917251e5-ff78-41ed-befd-1f204fe59b58"
      unitRef="U_USD">1529.04</ffd:TtlFeeAmt>
    <ffd:TtlPrevslyPdAmt
      contextRef="C_b67b64d4-632e-4174-b75e-0818148a4680"
      decimals="0"
      id="F_3543b63c-e5ea-4214-ba36-4aadb5a36849"
      unitRef="U_USD">0</ffd:TtlPrevslyPdAmt>
    <ffd:NetFeeAmt
      contextRef="C_b67b64d4-632e-4174-b75e-0818148a4680"
      decimals="2"
      id="F_e49ebe29-5d96-4b6c-8cee-2b658ed8c118"
      unitRef="U_USD">1529.04</ffd:NetFeeAmt>
    <ffd:OfferingNote
      contextRef="C_5b562405-3aa3-436a-aaf1-13bdf1f0b88b"
      id="F_9c3c390a-b851-4c3f-a482-acc265df649f">&lt;div class="item-list-element-wrapper" style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;"&gt;(1)&lt;/span&gt;&lt;div style="display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;amount registered represents shares of Common Stock (&#x201c;Common Stock&#x201d;) of Artiva Biotherapeutics, Inc. (the &#x201c;Registrant&#x201d;) that were automatically added to the shares authorized for issuance under the 2024 Equity Incentive Plan (the &#x201c;Incentive Plan&#x201d;) on January 1, 2026, pursuant to an &#x201c;evergreen&#x201d; provision contained in the Incentive Plan. Pursuant to such provision, on January 1st of each year through (and including) January 1, 2034, in an amount equal to 5% of the total number of shares of Common Stock outstanding on December 31 of the preceding year; provided, however, that the Registrant&#x2019;s board of directors may act prior to January 1st of a given year to provide that the increase for such year will be a lesser number of shares of Common Stock. Pursuant to Rule 416(a) under the Securities Act of 1933, as amended (the &#x201c;Securities Act&#x201d;), this Registration Statement shall also cover any additional shares of Common Stock of the Registrant that become issuable under the Registrant&#x2019;s Incentive Plan by reason of any stock dividend, stock split, recapitalization or other similar transaction. The proposed maximum offering price per share and maximum aggregate offering price are estimated &lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div class="item-list-element-wrapper" style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;visibility:hidden;word-break:keep-all;display:inline-flex;justify-content:flex-start;"&gt;&lt;/span&gt;&lt;div style="display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;solely &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;for the purpose of calculating the amount of the registration fee pursuant to Rule 457(c) and Rule 457(h) of the Securities Act using the average of the high and low prices of the Common Stock as reported on the Nasdaq Global Market on March 3, 2026 (the &#x201c;Average Price&#x201d;).&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;</ffd:OfferingNote>
    <ffd:OfferingNote
      contextRef="C_1f6ba287-de75-4191-aff3-3d93b1ebd441"
      id="F_6e8bf6c8-f2b7-4ef9-b1ce-30e8d9bf6229">&lt;div class="item-list-element-wrapper" style="display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;"&gt;(2)&lt;/span&gt;&lt;div style="display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The amount registered represents the shares of Common Stock that were automatically added to the shares authorized for issuance under the Registrant&#x2019;s 2024 Employee Stock Purchase Plan (the &#x201c;Employee Plan&#x201d;) on January 1, 2026, pursuant to an &#x201c;evergreen&#x201d; provision contained in the Employee Plan. Pursuant to such provision, on January 1st of each year through (and including) January 1, 2034, in an amount equal to the lesser of (i) 1% of the total number of shares of Common Stock outstanding on December 31st of the preceding calendar year and (ii) 424,000 shares of Common Stock; provided, however, that the Registrant&#x2019;s board of directors may act prior to January 1st of a given year to provide that there will be no increase in the share reserve for such calendar year or that the increase for such year will be a lesser number of shares of Common Stock than would otherwise occur. Pursuant to Rule 416(a) under the Securities Act this Registration Statement shall also cover any additional shares of Common Stock of the Registrant that become issuable under the Employee Plan by reason of any stock dividend, stock split, recapitalization or other similar transaction. The proposed maximum aggregate offering price per share and proposed maximum aggregate offering price are estimated solely for the purpose of calculating the amount of the registration fee pursuant to Rule 457(h) of the Securities Act on the basis of the Average Price, multiplied by 85%, which is the percentage of the price per share applicable to purchases under the Employee Plan.&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;</ffd:OfferingNote>
    <ffd:OfferingNote
      contextRef="C_661ecd0f-8d3e-4507-b11b-166454042432"
      id="F_920648a9-7cff-4506-ae01-24cdd4436937">&lt;div class="item-list-element-wrapper" style="display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;"&gt;(3)&lt;/span&gt;&lt;div style="display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The amount registered represents the shares of Common Stock that are authorized for issuance under the Registrant&#x2019;s 2025 Inducement Plan (the &#x201c;Inducement Plan&#x201d;). Pursuant to Rule 416(a) under the Securities Act this Registration Statement shall also cover any additional shares of Common Stock of the Registrant that become issuable under the Inducement Plan by reason of any stock dividend, stock split, recapitalization or other similar transaction. The proposed maximum aggregate offering price per share and proposed maximum aggregate offering price are estimated solely for the purpose of calculating the amount of the registration fee pursuant to Rule 457(c) and Rule 457(h) of the Securities Act using the Average Price.&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;</ffd:OfferingNote>
</xbrl>
